Form 10-K IONIS PHARMACEUTICALS For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
February 20, 2025 5:50 AM ESTRaymond James analyst Gary Nachman lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $60.00 (from $61.00) while maintaining a Strong Buy rating.
The analyst comments "Key Updates. 1) Wainua in ATTR-PN. AZN booked $42M in 4Q (+83% q/q; FY $86M), with ~$10M royalties to IONS (FY $20M). U.S. launch is progressing well with new-to-brand share ~40%; seeing good... More
